Nafithromycin - Wockhardt

Drug Profile

Nafithromycin - Wockhardt

Alternative Names: WCK 4873

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Hexoses; Ketolides; Lactones; Pyridines; Thiadiazoles
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia
  • Preclinical Haemophilus infections

Most Recent Events

  • 22 Apr 2017 Pharmacodynamics data from a preclinical study in Haemophilus infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 16 Sep 2016 Wockhardt plans a phase II trial for Community-acquired pneumonia in USA, Bulgaria, Latvia, Georgia, Romania, Russia, South Africa, Serbia and Montenegro (PO) (NCT02903836)
  • 01 Sep 2016 Phase-II clinical trials in Community-acquired pneumonia in Latvia, Bulgaria, USA (PO) (EudraCT2016-001246-26) (NCT02903836)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top